Classical veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) is a serious complication post allogeneic hematopoietic stem cell transplantation (HSCT). Before the recently revised EBMT criteria, the Baltimore and modified Seattle criteria failed to recognize the syndrome of late-onset VOD. We present real-world experience from a...
-
2021 (v1)PublicationUploaded on: February 11, 2024
-
2024 (v1)Publication
Background: Allogeneic haematopoietic stem-cell transplant is an option, potentially curative, for high-risk acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS) patients. Post-transplant cyclophosphamide administration allows for the selection of haploidentical donors in patients who are eligible for the procedure but do not have a...
Uploaded on: February 28, 2024 -
2023 (v1)Publication
Background: The second decade of this millennium was characterized by a widespread availability of chimeric antigen receptor T-cell (CAR-T) therapies to treat relapsed and refractory lymphomas. As expected, the role and indication of allogeneic haematopoietic stem cell transplant (allo-HSCT) in the management of lymphoma changed. Currently, a...
Uploaded on: February 13, 2024 -
2021 (v1)Publication
No description
Uploaded on: February 6, 2024 -
2022 (v1)Publication
No description
Uploaded on: February 14, 2024 -
2023 (v1)Publication
Background: Allogeneic haematopoietic stem cell transplant (HSCT) is a curative strategy for acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS). The prediction of transplant related mortality (TRM) using the HCT-CI score and an arbitrary upper limit of 55 years for administering myeloablative conditioning (MAC) are common...
Uploaded on: February 13, 2024 -
2020 (v1)Publication
No description
Uploaded on: February 14, 2024